scholarly journals Contribution of Central Abnormalities to Exertional Dyspnea and Ventilatory Response in Heart Failure with Preserved Ejection Fraction

2017 ◽  
Vol 23 (8) ◽  
pp. S10
Author(s):  
Masaru Obokata ◽  
Thomas P. Olson ◽  
Yogesh N.V. Reddy ◽  
Barry A. Borlaug
2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Shiro Amanai ◽  
Tomonari Harada ◽  
Kazuki Kagami ◽  
Kuniko Yoshida ◽  
Toshimitsu Kato ◽  
...  

AbstractExercise intolerance is a primary manifestation in patients with heart failure with preserved ejection fraction (HFpEF) and is associated with abnormal hemodynamics and a poor quality of life. Two multiparametric scoring systems have been proposed to diagnose HFpEF. This study sought to determine the performance of the H2FPEF and HFA-PEFF scores for predicting exercise capacity and echocardiographic findings of intracardiac pressures during exercise in subjects with dyspnea on exertion referred for bicycle stress echocardiography. In a subset, simultaneous expired gas analysis was performed to measure the peak oxygen consumption (VO2). Patients with HFpEF (n = 83) and controls without HF (n = 104) were enrolled. The H2FPEF score was obtainable for all patients while the HFA-PEFF score could not be calculated for 23 patients (feasibility 88%). Both H2FPEF and HFA-PEFF scores correlated with a higher E/e′ ratio (r = 0.49 and r = 0.46), lower systolic tricuspid annular velocity (r =  − 0.44 and =  − 0.24), and lower cardiac output (r =  − 0.28 and r =  − 0.24) during peak exercise. Peak VO2 and exercise duration decreased with an increase in H2FPEF scores (r =  − 0.40 and r =  − 0.32). The H2FPEF score predicted a reduced aerobic capacity (AUC 0.71, p = 0.0005), but the HFA-PEFF score did not (p = 0.07). These data provide insights into the role of the H2FPEF and HFA-PEFF scores for predicting exercise intolerance and abnormal hemodynamics in patients presenting with exertional dyspnea.


2008 ◽  
Vol 7 ◽  
pp. 62-63
Author(s):  
J NUNEZ ◽  
L MAINAR ◽  
G MINANA ◽  
R ROBLES ◽  
J SANCHIS ◽  
...  

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.


Sign in / Sign up

Export Citation Format

Share Document